Published in Int J Epidemiol on November 24, 2009
Hepatocellular carcinoma and industrial epidemics. World J Gastroenterol (2011) 0.75
Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol (2009) 2.11
Clothing naked quackery and legitimising pseudoscience. BMJ (2011) 1.95
Secondhand smoke is the most frequent cause of child maltreatment. Eur J Pediatr (2010) 1.39
Hepatocellular carcinoma: a pledge for evidence-based medicine. Am J Med (2008) 1.28
Colonic pseudolipomatosis: clinical, endoscopical and pathological features in nine cases. Gastroenterol Clin Biol (2006) 1.17
Drug industry is now biggest defrauder of US government. BMJ (2012) 1.11
Smoking cessation: a paradise for an alternative to evidence-based medicine? Am J Med (2013) 1.07
Almost getting with the guidelines: fame or shame? Am J Med (2013) 1.07
Rational policy for medical radiation: hype or hope? Am J Med (2013) 1.07
Screening for hepatocellular carcinoma: from lack of evidence to common sense. Hepatology (2010) 1.02
Screening for hepatocellular carcinoma: still in search for evidence based medicine? J Gastroenterol Hepatol (2006) 0.98
[Mass screening guidelines for prostate cancer: Should they be utilized in France?]. Can J Public Health (2007) 0.96
Registration of clinical trials. Ann Intern Med (2005) 0.91
Hepatocellular carcinoma. Lancet (2012) 0.89
Off-Label Drug Use: Whose Interests Are Served? Am J Med Qual (2016) 0.83
Alcohol and public health. Lancet (2005) 0.81
Is the American Association for the Study of Liver Diseases recommendation for hepatocellular carcinoma screening a cul-de-sac? World J Gastroenterol (2013) 0.79
Cancer screening: inequalities ... in the data. Int J Epidemiol (2010) 0.77
Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype? Eur J Intern Med (2007) 0.77
Marketing versus evidence-based medicine. Lancet (2012) 0.77
Polycystic ovary syndrome. N Engl J Med (2005) 0.76
Severe alcoholic hepatitis: glucocorticoid saves lives and transplantation is promising. World J Gastroenterol (2011) 0.76
[Social responsibility in health and the global health situation: towards new health and social indicators]. Sante Publique (2007) 0.75
[Letter on the article: "classifications and definitions of adverse events in primary care: a systematic review"]. Presse Med (2011) 0.75
Will evidence be enough to promote interactive communication for the benefit of patients? Ann Intern Med (2010) 0.75
Tobacco and liver transplantation: from medicine to surgery. Liver Transpl (2011) 0.75
A new French paradox: HBV vaccination. J Hepatol (2009) 0.75
Prostate specific antigen. Prostate screening in France. BMJ (2009) 0.75
Alcohol control policy: evidence-based medicine versus evidence-based marketing. Addiction (2011) 0.75
Colorectal cancer screening, ethics and evidence-based public policy. J Med Screen (2011) 0.75
[Letter on the article: "Non-communicable chronic diseases, a global public health priority recognized by the United Nations"]. Presse Med (2011) 0.75
Should we trust results of meta-analyses? Lancet (2004) 0.75
Vinflunine for non-small cell lung cancer: realistic hopes? J Thorac Oncol (2011) 0.75
Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries. Med J Aust (2011) 0.75
Do patients screened for hepatocellular carcinoma die significantly older? Gut (2011) 0.75
Safety of percutaneous liver biopsy: statistics, semantics, and citations. J Clin Gastroenterol (2011) 0.75
Hepatocellular carcinoma and evidence-based surgery. World J Gastroenterol (2009) 0.75
Trouble with translational medicine and bad news for mice. J Intern Med (2011) 0.75
Homoeopathic remedies and drug-regulatory authorities. Lancet (2010) 0.75
Alpha-1 antitrypsin deficiency and liver disease. Am J Med (2008) 0.75
Whistleblowing: neither reward, nor protection. J Public Health Policy (2010) 0.75
Can pregnant women in Blackpool wait for further research? Lancet (2013) 0.75
Medical devices and the approval processes: United States vs France. Arch Intern Med (2010) 0.75
Experience is a gloomy lantern that does not even illuminate its bearer. Arch Intern Med (2012) 0.75
Should we trust the results of multivariate analysis? J Gastrointest Surg (2009) 0.75
Is this clinical trial fully registered? CMAJ (2006) 0.75
Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 0.75
Developers of the hepatitis B vaccine. JAMA (2009) 0.75
Prostate cancer screening: Unacceptable in the under 50s. BMJ (2007) 0.75
Why use Markov simulation models for estimating the effect of cancer screening policies when randomised controlled trials provide better evidence? Stat Methods Med Res (2012) 0.75
Re: Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur urol 2011;60:279-90. Eur Urol (2011) 0.75
Challenging special interest groups: whistleblowers may help. Help them! Psychother Psychosom (2011) 0.75
Illusion is disease mongering. BMJ (2008) 0.75
Generic competition in a flawed system: pill them, bill them. Arch Intern Med (2012) 0.75
Smoking is a greater source of health inequality than educational level (EL). Eur J Obstet Gynecol Reprod Biol (2010) 0.75
The enigma of spontaneous preterm birth. N Engl J Med (2010) 0.75
EMA urgently needs a cure. BMJ (2011) 0.75
Tobacco harm to the developing child. Eur J Pediatr (2010) 0.75
Public health, politicians' decisions, and the citizen. Health Policy (2009) 0.75
Number needed to treat: implementation for diets. Arch Intern Med (2011) 0.75
Give the Sahara desert to a health care administrator and a few weeks later he will have to import sand. Am J Med Qual (2008) 0.75
Who will fear the Commission on Global Governance for Health? Lancet (2012) 0.75
Implement research faster. CMAJ (2010) 0.75
Credibility of industry-sponsored clinical research: hype or hope? Mayo Clin Proc (2012) 0.75
European Prospective Investigation into Cancer and Nutrition (EPIC): methods and clinical relevance. Am J Clin Nutr (2011) 0.75
Computerized hospitals: not all that glitters is gold. Am J Med (2010) 0.75
Sciensationalism. Am J Med (2010) 0.75
Taxing "Sin drinks": from economy to sugar control. Prev Med (2011) 0.75
Can surrogate end points from a first-round screening be reliable for colorectal cancer screening? Gastroenterology (2012) 0.75
Hepatocellular carcinoma and industrial epidemics. World J Gastroenterol (2011) 0.75
HBV vaccination coverage among health-care workers. Eur J Public Health (2011) 0.75
[Medical devices approval process, a new French exception?]. Presse Med (2011) 0.75
Lost opportunity to usefully examine French breast cancer screening mortality. Cancer Epidemiol (2011) 0.75
Hepatocellular carcinoma: still in search of evidence-based care. Clin Gastroenterol Hepatol (2011) 0.75
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology (2009) 0.75
Hepatocellular carcinoma and gene profiling: back from perspective to reality. Hepatology (2011) 0.75
Baclofen and protecting the patients during research. Alcohol Alcohol (2012) 0.75
Violence during pregnancy. What about smoking? Acta Obstet Gynecol Scand (2010) 0.75
Liver transplantation: from guidelines to randomized controlled trials. Ann Surg (2010) 0.75
Colorectal cancer screening: from perspectives to reality. Gastroenterology (2010) 0.75
Responses to increasing cigarette prices in France: how did the tobacco lobby react? Health Policy (2012) 0.75
How to dispel myths in the treatment of hepatic encephalopathy? Nat Clin Pract Gastroenterol Hepatol (2007) 0.75
The women's conspiracy. Lancet (2007) 0.75
Nutrition and nonalcoholic fatty liver disease? Still in search of evidence! Am J Gastroenterol (2007) 0.75
Engraving marble and comparative effectiveness reviews. J Clin Epidemiol (2011) 0.75
Surveillance for hepatocellular carcinoma. Ann Intern Med (2011) 0.75
Pregnancy and hepatitis B in Europe. Liver Int (2009) 0.75
Effects of fibrates on cardiovascular outcomes. Lancet (2010) 0.75
World Oncology Forum and commercial sponsorship. Lancet (2013) 0.75
Mediator: who's to blame? Lancet (2011) 0.75
Can selection bias in trials allow hydrochlorothiazide to be banned? Am J Med (2012) 0.75
Re: Is a screening interval of every 4 years for prostate cancer acceptable? J Natl Cancer Inst (2008) 0.75
Surveillance programmes for hepatocellular carcinoma: evident-based medicine is not evidence-based medicine. Liver Int (2009) 0.75
Hepatocellular carcinoma: sorafenib before liver transplantation? Hepatology (2010) 0.75
Prediction and statistical analysis. Arch Surg (2011) 0.75